Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone with Sunitinib or Dasatinib in Advanced Prostate Cancer
NCT01254864Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2011
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib, dasatinib in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2011; status: completed.
02
Drugs
sunitinibdasatinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01254864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01254864.